A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide
Molecular Pharmaceutics · 2026
DOI: 10.1021/acs.molpharmaceut.6c00580 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2026. Verfasst von Mengqiao Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, and School of Life Scien…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-mdm2, Camptothecin, Peptides. Die Arbeit nennt 50 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai, Shanghai Jiao Tong University, National Basic Research Program of China (973 Program).
Abstract (Originalsprache)
Regulation of the tumor suppressor p53 is a promising approach for cancer treatment; however, a single regulatory method often shows limited efficacy. Here, we develop an affibody-drug conjugate nanoagent (ADCN) for the targeted codelivery of topoisomerase I inhibitor DX8591 and p53-MDM2 inhibitor PMI to upregulate p53 levels in cancer cells. The tripartite conjugate ZEGFR:1907-PMI-DX8591 self-assembled into nanoparticles with an average diameter of 74.4 nm, resulting in improved pharmacokinetic profiles and enhanced tumor-targeting ability. After efficient EGFR-mediated cellular uptake, the ZEGFR:1907-PMI-DX8591 ADCN released DX8591 and PMI intracellularly, leading to synergistic p53 activation by inducing p53 production and blocking its degradation. In EGFR-positive non-small cell lung tumor models, the ADCN showed excellent tumor accumulation and achieved 81.7% tumor growth inhibition, which was 1.5-fold and 1.2-fold higher than those of the ZEGFR:1907-PMI and ZEGFR:1907-DX8591 monotherapies, respectively. This affibody-based delivery system provides a promising strategy for synergistic cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Microbial Metabolism, Joint International Research Laboratory of Metabolic & Developmental Sciences, and School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Ro…
- State Key Laboratory of Synergistic Chem-Bio Synthesis, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai200240, People's Republic of China.
ORCID-Profile: Wenhui Gao, Xuelin Xia, Xiao-Xia Xia, Zhi-Gang Qian
Förderung
- Natural Science Foundation of Shanghai
- Shanghai Jiao Tong University
- National Basic Research Program of China (973 Program)
- Science and Technology Innovation Plan Of Shanghai Science and Technology Commission
- State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Jiao Tong University
Zitieren
APA
Zhao, M., Gao, W., Xia, X., Xia, X. X., & Qian, Z. G. (2026). A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00580
Vancouver
Zhao M, Gao W, Xia X, Xia XX, Qian ZG. A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide. Molecular Pharmaceutics. 2026. doi:10.1021/acs.molpharmaceut.6c00580
BibTeX
@article{Zhao2026,
author = {Zhao, Mengqiao and Gao, Wenhui and Xia, Xuelin and Xia, Xiao-Xia and Qian, Zhi-Gang},
title = {A Self-Assembled Affibody-Drug Conjugate Nanoagent for EGFR-Targeted Synergistic Codelivery of Exatecan and an MDM2 Inhibitory Peptide},
journal = {Molecular Pharmaceutics},
year = {2026},
doi = {10.1021/acs.molpharmaceut.6c00580}
}
EUVIMED